Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized neoadjuvant anastrozole versus fulvestrant in postmenopausal hormone-sensitive non-metastatic breast cancer
2007-004216-31Phase 2Completed
- Sponsor
- Institut Bergonié
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer and hormone receptor-positive breast cancer comparing Anastrozole with Fulvestrant (2 arms). Primary endpoints: Clinical tumor response at 6 months and Tumor evaluation over time. Started Aug 2007; status: completed.
02
Drugs
anastrozolefulvestrant
03
Conditions
breast cancerhormone receptor-positive breast cancer
Beyond the preview
Go deeper on 2007-004216-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004216-31.